The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale
- PMID: 17610339
- DOI: 10.2165/00019053-200725070-00005
The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale
Abstract
Introduction: The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a validated, sensitive and reliable patient questionnaire that evaluates and quantifies quality of life (QOL) across several domains, including lung cancer-related symptoms. The FACT-L was not designed for use in economic evaluation and does not incorporate preferences into its scoring system.
Objective: To derive a set of Dutch preference weights for FACT-L health states that can be used to convert FACT-L into a single value that can be used in cost-utility analyses.
Methods: A representative sample of the Dutch population (n = 1076) directly valued an orthogonal set of eight FACT-L health states on a 100-point rating scale with the anchor points 'worst imaginable health state' and 'best imaginable health state'. Eleven FACT-L items were selected to describe the FACT-L health states that were directly valued. Regression analysis was used to interpolate values for all other possible health states. Scores were transformed into values on a scale where 0 indicated dead and 1 indicated full health.
Results: The estimated values for FACT-L health states ranged from 0.08 to 0.93. The estimated value sets were applied to FACT-L data of lung cancer patients participating in a clinical study. Significant differences in the mean value and mean gain of 0.12 and 0.07, respectively, were found between patients in remission and patients with progressive disease at 4 weeks' follow-up.
Conclusion: Our results reaffirmed that the methodology used here is a feasible option to convert data collected with a disease-specific outcome measure into preferences. We concluded that the sensitivity of the derived set of societal preferences to capture differences and changes in clinical health states is an indication of its construct validity.
Similar articles
-
Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states.Pharmacoeconomics. 2005;23(11):1143-53. doi: 10.2165/00019053-200523110-00006. Pharmacoeconomics. 2005. PMID: 16277549
-
Comparison of FACT- and EQ-5D-based utility scores in cancer.Value Health. 2012 Mar-Apr;15(2):305-11. doi: 10.1016/j.jval.2011.11.029. Epub 2012 Feb 2. Value Health. 2012. PMID: 22433762
-
Estimating a Preference-Based Value Set for the Mental Health Quality of Life Questionnaire (MHQoL).Med Decis Making. 2024 Jan;44(1):64-75. doi: 10.1177/0272989X231208645. Epub 2023 Nov 19. Med Decis Making. 2024. PMID: 37981788 Free PMC article.
-
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review.
-
Novel Augmentation Strategies in Major Depression.Dan Med J. 2017 Apr;64(4):B5338. Dan Med J. 2017. PMID: 28385173 Review.
Cited by
-
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE).Pharmacoeconomics. 2015 Aug;33(8):867-77. doi: 10.1007/s40273-015-0292-9. Pharmacoeconomics. 2015. PMID: 26026667 Free PMC article.
-
Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer.Pharmacoeconomics. 2020 Nov;38(11):1187-1200. doi: 10.1007/s40273-020-00947-x. Pharmacoeconomics. 2020. PMID: 32754857 Free PMC article.
-
Evaluation of content on EQ-5D as compared to disease-specific utility measures.Qual Life Res. 2013 May;22(4):853-74. doi: 10.1007/s11136-012-0207-6. Epub 2012 Jun 23. Qual Life Res. 2013. PMID: 22729670 Review.
-
A Patient-Centered Utility Index for Non-Small Cell Lung Cancer in the United States.MDM Policy Pract. 2018 Oct 15;3(2):2381468318801565. doi: 10.1177/2381468318801565. eCollection 2018 Jul-Dec. MDM Policy Pract. 2018. PMID: 30349874 Free PMC article.
-
Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands.Health Qual Life Outcomes. 2012 Sep 10;10:108. doi: 10.1186/1477-7525-10-108. Health Qual Life Outcomes. 2012. PMID: 22963131 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical